BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Kidney tumors AND BRCA2, FAD, 675, ENSG00000139618, FACD, FAD1, FANCD, FANCD1, BRCC2, RP11-298P3_4 AND Treatment
8591 results:

  • 1. Does depressurization of the portal vein before liver transplantation affect the recurrence of HCC? A nested case-control study.
    Wei G; Zhao Y; Feng S; Yuan J; Xu G; Lv T; Yang J; Kong L; Yang J
    BMC Cancer; 2024 May; 24(1):558. PubMed ID: 38702621
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. A retrospective clinical analysis of 11 cases of PEComa from different sites.
    Yan J; Zhou D; Wang Y; Yang B; Wang Y; Zhang K; Zhang S; Zhang B; Meng Q; Lv Q
    World J Surg Oncol; 2024 Apr; 22(1):116. PubMed ID: 38689335
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma.
    Rahman SN; Long JB; Westvold SJ; Leapman MS; Spees LP; Hurwitz ME; McManus HD; Gross CP; Wheeler SB; Dinan MA
    JAMA Netw Open; 2024 Apr; 7(4):e248747. PubMed ID: 38687479
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Genetic polymorphisms and clinical parameters associated with renal toxicity in Thai hematologic malignancy patients receiving high dose methotrexate.
    Pitakkitnukun P; Pongpitakmetha T; Suttichet TB; Sukkummee W; Chariyavilaskul P; Polprasert C
    Sci Rep; 2024 Apr; 14(1):9695. PubMed ID: 38678107
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Crosstalk of disulfidptosis-related subtypes identifying a prognostic signature to improve prognosis and immunotherapy responses of clear cell renal cell carcinoma patients.
    Ren L; Liu J; Lin Q; He T; Huang G; Wang W; Zhan X; He Y; Huang B; Mao X
    BMC Genomics; 2024 Apr; 25(1):413. PubMed ID: 38671348
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Squamous Cell Carcinoma Arising From Epidermal Cyst: A Case Series of 9 Patients With a Literature Review.
    Kim JY; Min S; Park JK; Kim SW
    Ann Plast Surg; 2024 May; 92(5):575-579. PubMed ID: 38669586
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Octamer-binding transcription factor 4-positive circulating tumor cell predicts worse treatment response and survival in advanced cholangiocarcinoma patients who receive immune checkpoint inhibitors treatment.
    Pei F; Tao Z; Lu Q; Fang T; Peng S
    World J Surg Oncol; 2024 Apr; 22(1):110. PubMed ID: 38664770
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Increased level of serum leucine-rich-alpha-2-glycoprotein 1 in patients with clear cell renal cell carcinoma.
    Nakanishi S; Goya M; Suda T; Yonamine T; Sugawa A; Saito S
    BMC Urol; 2024 Apr; 24(1):94. PubMed ID: 38658967
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Comparison of skin cancer risk between renal transplant recipients and patients with glomerular diseases in rural Queensland.
    Thet Z; Lam AK; Ng SK; Aung SY; Han T; Ranganathan D; Newsham S; Borg J; Pepito C; Khoo TK
    Aust J Rural Health; 2024 Apr; 32(2):249-262. PubMed ID: 38646861
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Ablation of kidney tumors in Patients with Substantial kidney Impairment: Current Status.
    Iguchi T; Matsui Y; Tomita K; Uka M; Umakoshi N; Kawabata T; Gobara H; Araki M; Hiraki T
    Curr Oncol Rep; 2024 May; 26(5):573-582. PubMed ID: 38625653
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas.
    Roskoski R
    Pharmacol Res; 2024 May; 203():107181. PubMed ID: 38614375
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A).
    Atkins MB; Jegede OA; Haas NB; Mcdermott DF; Bilen MA; Stein M; Sosman J; Alter R; Plimack ER; Ornstein MC; Hurwitz M; Peace DJ; Einstein D; Catalano PJ; Hammers H; Regan MM
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38604810
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Clinical safety and efficacy of microwave ablation for small renal masses.
    Foret A; Haaga CB; Jain S; Baumgartner CO; Escott M; Henderson BR; O'Brien ST; Delacroix SE; Gills JRR; Westerman ME
    Int Braz J Urol; 2024; 50(3):277-286. PubMed ID: 38598830
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Ablative Radioembolization (SIRT) of a Large Inoperable Renal Cell Carcinoma Invading the Liver That Resulted in Hematuria Control and Complete Necrosis by mRECIST Criteria.
    Spyridonidis I; Dimopoulos P; Spyridonidis T; Christopoulou A; Katsanos K
    Clin Nucl Med; 2024 Jun; 49(6):557-558. PubMed ID: 38598452
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. [Discussion on the surgical timing of rupture and hemorrhage of renal angiomyolipoma].
    Chen K; Deng S; Liu Z; Zhang H; Ma L; Zhang S
    Beijing Da Xue Xue Bao Yi Xue Ban; 2024 Apr; 56(2):326-331. PubMed ID: 38595253
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Conversion to Radical Nephrectomy From Robotic Partial Nephrectomy Is Most Commonly Due to Anatomic and Oncologic Complexity.
    Wang Y; Wilder S; Butaney M; Hijazi M; Gandham D; Van Til M; Goldman B; Qi J; Mirza M; Johnson A; Rudoff M; Wenzler D; Rogers CG; Lane BR
    J Urol; 2024 May; 211(5):669-676. PubMed ID: 38591701
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Challenges and technical aspects in the management of muscle invasive bladder cancer as retrograde radical cystectomy with ileal conduit.
    Nusrat NB; Rehman AU; Zafar N; Muhammad S; Bajwa SI; Imtiaz S
    J Pak Med Assoc; 2024 Mar; 74(3):513-518. PubMed ID: 38591289
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Safety and efficacy of nivolumab therapy in patients with metastatic renal cell carcinoma and impaired kidney function.
    Sengul N; Gültürk I; Yilmaz M; Celik E; Paksoy N; Yekedüz E; Ürün Y; Basaran M; Özgüroğlu M
    Actas Urol Esp (Engl Ed); 2024 May; 48(4):273-280. PubMed ID: 38570033
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Ononin triggers ferroptosis-mediated disruption in the triple negative breast cancer both in vitro and in vivo.
    Gong G; Wan Y; Liu Y; Zhang Z; Zheng Y
    Int Immunopharmacol; 2024 May; 132():111959. PubMed ID: 38554442
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Comparison of three equations for estimating glomerular filtration rate as predictors of cisplatin-related acute kidney injury in lung cancer patients with normal renal function.
    Karaboyun K; İriağaç Y; Çavdar E; Avci O; Şeber ES
    J Cancer Res Ther; 2024 Jan; 20(1):144-149. PubMed ID: 38554312
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 430.